<DOC>
	<DOCNO>NCT01789398</DOCNO>
	<brief_summary>This multicentric international phase III , double blind randomize study assess efficacy safety parallel group BF2.649 ( pitolisant ) compare placebo add-on sodium oxybate narcoleptic patient residual Excessive Daytime Sleepiness ( EDS ) 8 week</brief_summary>
	<brief_title>Patient Narcoleptic Treated With BF2.649 ( Pitolisant ) add-on Sodium Oxybate ( HARMONY IV )</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>Males female , age 18 year old . Patients diagnosis narcolepsy accord International Classification Sleep Disorders ( ICSD2 ) criterion Patients treat sodium oxybate ( Xyrem® ) stable dosage least 2 month prior trial . Patients complain residual EDS Patient free non authorize drug discontinue psychostimulant medication least 3 week randomization ( V2 ) . Females childbearing potential must use medically accepted effective method birth control , agree continue method duration study negative serum pregnancy test perform screen visit . Females breastfeed patient . In opinion investigator , patient must adequate support comply entire study requirement describe protocol ( e.g . transportation trial site , self rating scale , drug compliance , schedule visit , etc ) . Patient must voluntarily express willingness participate study , sign date informed consent prior begin protocol require procedure . Psychiatric neurological disorder , narcolepsy/cataplexy , moderate severe psychosis dementia , bipolar illness , severe anxiety , clinical severe depression ( BDI ≥ 16 ) suicidal risk ( item G BDI &gt; 0 ) , depression treat less 8 week , history seizure disorder problem investigator 's opinion would preclude patient 's participation completion trial comprise reliable representation subjective symptom . Patients work occupation require variable shift work routine night shift . Patients untreated sleep apnea disorder ( define apnea index &gt; 10/h apnea/hypopnea index &gt; 15/h ) cause daytime sleepiness . Use hypnotic , tranquilizer , sedate antihistamine , psychostimulants treatment EDS ( amphetamine amphetaminelike CNS stimulant , modafinil , methylphenidate others ) , benzodiazepine , anticonvulsant clonidine accept least 3 week randomization ( V2 ) study . Current recent ( within one year ) history substance abuse dependence disorder include alcohol abuse define Diagnostic Statistical Manual Mental Disorders ( DSMIV ) . Other active clinically significant illness , include unstable cardiovascular , neoplasic pathology could interfere study conduct counterindicate study treatment place patient risk trial compromise study participation . Patient known history long QTc syndrome ( e.g . syncope arythmia ) present significant serious abnormality ECG ( e.g . recent myocardial infarction ) , QTc interval strictly high 450 m ( electrocardiogram Bazett 's correct ) . Patients Severe Hepatic Impairment Severe Renal Impairment , significant abnormality physical examination clinical laboratory result . Known hypersensitivity test treatment include active substance excipients . Patients participate study use investigational therapy within 30 day prior entry study . Patient without medical care insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>